-
Mashup Score: 0
ASCO GU 2021 Genitourinary Cancers Symposium – Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Radium-223 (Ra-223) Treatment of Metastatic Castration-Resistant Prostate Cancer (McRpc) That Progressed After First-Line NAH, prostate cancer, real-world clinical outcomes study, radium-223
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
ASCO GU 2021 Genitourinary Cancers Symposium – Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Radium-223 (Ra-223) Treatment of Metastatic Castration-Resistant Prostate Cancer (McRpc) That Progressed After First-Line NAH, prostate cancer, real-world clinical outcomes study, radium-223
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or Ra-223 treatment of #mCRPC that progressed after first-line NAH. Presented by @sartor_oliver @NolaBlueDoo. #GU21 session summary by @WallisCJD @UofT on UroToday > https://t.co/WVlFWji7G0 @ASCO https://t.co/UGkkOCWKXX
-
-
Mashup Score: 0
ASCO GU 2021 Genitourinary Cancers Symposium – Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Radium-223 (Ra-223) Treatment of Metastatic Castration-Resistant Prostate Cancer (McRpc) That Progressed After First-Line NAH, prostate cancer, real-world clinical outcomes study, radium-223
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or Ra-223 treatment of #mCRPC that progressed after first-line NAH. Presented by @sartor_oliver @NolaBlueDoo. #GU21 session summary by @WallisCJD @UofT on UroToday > https://t.co/WVlFWji7G0 @ASCO https://t.co/Qkod16dn1t
-
-
Mashup Score: 1
ASCO GU 2021 Genitourinary Cancers Symposium, A Prospective Phase II/III Study of PSMA-Targeted 18F-DCFPyL-PET/CT in Patients with Prostate Cancer (PCa) (OSPREY): A Subanalysis of Disease Staging Changes in PCa Patients with Recurrence or Metastases on Conventional Imaging.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 7ASCO GU 2021: CTC Counts as a Biomarker of Prognosis and Response in Metastatic Castration-Resistant Prostate Cancer (mCRPC) from the CARD Trial - 2 year(s) ago
2021 ASCO GU Cancers Symposium CARD trial, cabazitaxel treatment demonstrated significantly improved progression-free survival (rPFS) and overall survival (OS), assessing the role of circulating tumor cell (CTC) counts.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 2
ASCO GU 2021 Genitourinary Cancers Symposium Cabazitaxel second-line chemotherapy setting, feasibility and efficacy of cabazitaxel in patients with mCRPC.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Cabazitaxel multiple rechallenges in metastatic castration-resistant #ProstateCancer: a therapeutic option to increase overall survival? Presentation by @CedricPobel @HopitalPompidou. #GU21 written coverage by @WallisCJD @VUMCurology on UroToday > https://t.co/Y8El70tyKZ @ASCO https://t.co/p3p2n7b2Fu
-
-
Mashup Score: 2
ASCO GU 2021 Genitourinary Cancers Symposium Cabazitaxel second-line chemotherapy setting, feasibility and efficacy of cabazitaxel in patients with mCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Cabazitaxel multiple rechallenges in metastatic castration-resistant #ProstateCancer: a therapeutic option to increase overall survival? Presentation by @CedricPobel @HopitalPompidou. #GU21 written coverage by @WallisCJD @VUMCurology on UroToday > https://t.co/Y8El70bXmp @ASCO https://t.co/xOd9BMVZzT
-
-
Mashup Score: 4
ASCO GU 2021 Genitourinary Cancers Symposium Cabazitaxel second-line chemotherapy setting, feasibility and efficacy of cabazitaxel in patients with mCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Cabazitaxel multiple rechallenges in metastatic castration-resistant #ProstateCancer: a therapeutic option to increase overall survival? Presentation by @CedricPobel @HopitalPompidou. #GU21 written coverage by @WallisCJD @VUMCurology on UroToday > https://t.co/Y8El70tyKZ @ASCO https://t.co/BmWAantJn6
-
-
Mashup Score: 0Homologous recombination repair pathway alterations in mHSPC - 3 year(s) ago
Rana McKay, MD, University of California San Diego, San Diego, CA, discusses the prognostic significance of homologous recombination repair pathway…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The 2021 Genitourinary (GU) Cancers Symposium was held in a virtual format on February 11–13 and featured the latest developments in the understanding and treatment of genitourinary cancers. The impact of prostate cancer therapies on outcomes in older adults continues to be a growing area of research, and numerous…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or Ra-223 treatment of #mCRPC that progressed after first-line NAH. Presented by @sartor_oliver @NolaBlueDoo. #GU21 session summary by @WallisCJD @UofT on UroToday > https://t.co/WVlFWji7G0 @ASCO https://t.co/CEJSWXOFP2